All In Biotech

Drug Trial Radar · NCT07948122

Prospective Evaluation of Response to Treatment in Younger Adult Patients (18-60 Years) With Acute Myeloid Leukemia (AML)

Prospective Evaluation of Response to Treatment by Analysis of Measurable Residual Disease in Younger Adult Patients (18-60 Years) With Acute Myeloid Leukemia (AML). The Backbone InterGroup (BIG)-2 Umbrella Trial From the Acute Leukemia French Intergroup (ALFA, FILO)

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 1,290 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,290

Planned (sponsor's estimate)

Start

Jan 4, 2027

Primary completion

Dec 31, 2035

Study completion Dec 31, 2037

Sponsor

Lead sponsor
University Hospital, ToulouseAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The treatment of younger AML patients fit for intensive chemotherapy (IC) has long been based on a combination of an anthracycline and cytarabine as induction, followed by high-dose cytarabine (HDAC) consolidation, and possibly allogeneic stem-cell transplantation at least in non-favorable risk AML patients. Even if new agents like gemtuzumab ozogamicin (GO), FLT3 inhibitors, or CPX-351 have been approved to treat some patient subsets, there has been no major therapeutic advances to date in this field. The first multicenter trial from the ALFA-FILO intergroup (Backbone InterGroup trial-1, BIG-1; NCT02416388; PHRC2010-03) randomly explored various standard intensive chemotherapy strategies, including higher-dose idarubicin vs. high-dose daunorubicin (DNR) and intermediate-dose cytarabine (IDAC) vs. HDAC in patients (18-60 years) with newly-diagnosed AML. This first part of the study, which enrolled 1405 participants between 01/2015 and 05/2019, showed that the benefit/risk ratio favored high-dose DNR for remission induction and IDAC consolidation, establishing the national standard treatment for younger AML patients. Six-year OS was 53.4% showing that there is still considerable room for improvement in this younger patient population. High-throughput sequencing and multiparametric flow cytometry have significantly improved prognostic classifications and the evaluation of response to therapy through the quantification of measurable residual disease (MRD). Many studies have shown that the higher the MRD, the higher the risk of relapse and death; and recent guidelines have included MRD in the response criteria. Achieving complete remission without MRD is a major goal after first-line treatment to guide subsequent treatments, including transplantation. Furthermore, MRD follow-up in patients who achieved complete remission is becoming a major issue, as patients treated for molecular relapse appear to have a better prognosis than patients treated for morphological relapse. Preliminary data also showed encouraging results from salvage treatment at the time of MRD relapse. Quizartinib (a second-generation FLT3-ITD inhibitor) and venetoclax (the first-in-class BCL-2 inhibitor) have been recently approved for the treatment of AML. Quizartinib was approved on the basis of a placebo-controlled trial but its added value compared to midostaurin (first FLT3 inhibitor available in this indication since 2018) has never been prospectively explored. Although venetoclax was approved for first line therapy of patients who are unfit for intensive chemotherapy, it is widely used in relapsed or refractory younger patients. Venetoclax combined with intensive salvage chemotherapy is feasible and induce a high rate of CR. However, no prospective, randomized trial demonstrated venetoclax efficacy in this setting.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • QuizartinibDrug

    Sub-study 1 : addition of quizartinib to induction chemotherapy (7+3) and to consolidation chemotherapy (intermediate-dose cytarabine) in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication Acute Myeloid Leukemia without Core Binding Factor Acute Myeloid Leukemia.

  • MidostaurinDrug

    Sub-Study 1: Addition of midostaurin to induction chemotherapy (7+3) and consolidation chemotherapy (intermediate-dose cytarabine) in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication Acute Myeloid Leukemia without Core Binding Factor Acute Myeloid Leukemia.

  • VenetoclaxDrug

    Sub-Study 2 : Addition of venetoclax to high-dose cytarabine after one cycle of induction in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication negative Acute Myeloid Leukemia (including Core Binding Factor Acute Myeloid Leukemia patients) and with a suboptimal response to 7+3 induction.

  • High-dose cytarabineDrug

    High-dose cytarabine after one cycle of induction in patients 18-60 years of age with newly diagnosed FLT3 internal tandem duplication negative Acute Myeloid Leukemia (including Core Binding Factor Acute Myeloid Leukemia patients) and with a suboptimal response to 7+3 induction.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sub-Study 1 : MRD responseTime frame: At the end of Cycle 1 (each cycle is 28 days)
  2. Sub-Study 2 : MRD response venetoclaxTime frame: At the end of Cycle 1 (each cycle is 28 days)
  3. Sub-Study 3 : Overall survivalTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 53 months

Locations

55 sites in 1 country. Site status is shown where the registry gives one.

  • CHU d'Amiens

    Amiens, France, France

  • CHU d'Angers

    Angers, France, France

  • CH Argenteuil

    Argenteuil, France, France

  • CHR de Metz-Thionville

    Ars-Laquenexy, France, France

  • CH Avignon

    Avignon, France, France

  • CH de Bayonne

    Bayonne, France, France

  • CHU de Besançon

    Besançon, France, France

  • CH de Béziers

    Béziers, France, France

  • CH d'Avicenne

    Bobigny, France, France

  • CHU de Brest

    Brest, France, France

  • CHU de Caen

    Caen, France, France

  • CH de Chambéry

    Chambéry, France, France

  • Hôpital Clamart Percy

    Clamart, France, France

  • CHU de Clermont-Ferrand

    Clermont-Ferrand, France, France

  • CH de Corbeil

    Corbeil-Essonnes, France, France

  • CH de Créteil

    Créteil, France, France

  • CHU de Dijon

    Dijon, France, France

  • CH de Dunkerque

    Dunkirk, France, France

  • CH Annecy Genevois

    Épagny, France, France

  • CHU de Grenoble

    Grenoble, France, France

  • CH de Versailles

    Le Chesnay, France, France

  • CH de Lens

    Lens, France, France

  • Hôpital Saint Vincent de Paul

    Lille, France, France

  • CHU de Lille

    Lille, France, France

  • CHU de Limoges

    Limoges, France, France

  • Centre Léon Bérard

    Lyon, France, France

  • CHU de Marseille

    Marseille, France, France

  • Institut Paoli Calmettes

    Marseille, France, France

  • CH de Meaux

    Meaux, France, France

  • CHU de Montpellier

    Montpellier, France, France

  • CH de Mulhouse

    Mulhouse, France, France

  • CHU de Nantes

    Nantes, France, France

  • CHU de Nice

    Nice, France, France

  • CHU de Nîmes

    Nîmes, France, France

  • CHU d'Orléans

    Orléans, France, France

  • Institut Curie

    Paris, France, France

  • Hôpital Saint-Louis

    Paris, France, France

  • Hôpital de la Pitié Salpêtrière

    Paris, France, France

  • Hôpital Cochin

    Paris, France, France

  • Hôpital Necker

    Paris, France, France

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.